These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29401638)

  • 1. Candidacidal Activity of a Novel Killer Toxin from Wickerhamomyces anomalus against Fluconazole-Susceptible and -Resistant Strains.
    Giovati L; Santinoli C; Ferrari E; Ciociola T; Martin E; Bandi C; Ricci I; Epis S; Conti S
    Toxins (Basel); 2018 Feb; 10(2):. PubMed ID: 29401638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation of a Wickerhamomyces anomalus yeast strain from the sandfly Phlebotomus perniciosus, displaying the killer phenotype.
    Martin E; Bongiorno G; Giovati L; Montagna M; Crotti E; Damiani C; Gradoni L; Polonelli L; Ricci I; Favia G; Epis S
    Med Vet Entomol; 2016 Mar; 30(1):101-6. PubMed ID: 26542209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The killer yeast Wickerhamomyces anomalus Cf20 exerts a broad anti-Candida activity through the production of killer toxins and volatile compounds.
    Fernández de Ullivarri M; Bulacios GA; Navarro SA; Lanza L; Mendoza LM; Chalón MC
    Med Mycol; 2020 Nov; 58(8):1102-1113. PubMed ID: 32196549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel killer toxin produced by the marine-derived yeast Wickerhamomyces anomalus YF07b.
    Guo FJ; Ma Y; Xu HM; Wang XH; Chi ZM
    Antonie Van Leeuwenhoek; 2013 Apr; 103(4):737-46. PubMed ID: 23180377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.
    Wang H; Xiao M; Chen SC; Kong F; Sun ZY; Liao K; Lu J; Shao HF; Yan Y; Fan H; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Xu YC
    J Clin Microbiol; 2012 Dec; 50(12):3952-9. PubMed ID: 23035204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Susceptibility of yeasts to antifungal agents in Kaunas University of Medicine Hospital].
    Skrodeniene E; Dambrauskiene A; Vitkauskiene A
    Medicina (Kaunas); 2006; 42(4):294-9. PubMed ID: 16687901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia?
    Kovacicova G; Krupova Y; Lovaszova M; Roidova A; Trupl J; Liskova A; Hanzen J; Milosovic P; Lamosova M; Macekova L; Szovenyiova Z; Purgelova A; Obertik T; Bille J; Krcmery V
    J Infect Chemother; 2000 Dec; 6(4):216-21. PubMed ID: 11810569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A yeast strain associated to Anopheles mosquitoes produces a toxin able to kill malaria parasites.
    Valzano M; Cecarini V; Cappelli A; Capone A; Bozic J; Cuccioloni M; Epis S; Petrelli D; Angeletti M; Eleuteri AM; Favia G; Ricci I
    Malar J; 2016 Jan; 15():21. PubMed ID: 26754943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017).
    Desnos-Ollivier M; Bretagne S; Boullié A; Gautier C; Dromer F; Lortholary O;
    Clin Microbiol Infect; 2019 May; 25(5):634.e1-634.e4. PubMed ID: 30771532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
    J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Plasma Membrane Pleiotropic Drug Resistance Transporters in the Killer Activity of
    Czarnecka M; Połomska X; Restuccia C; Żarowska B
    Toxins (Basel); 2022 Feb; 14(3):. PubMed ID: 35324677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Wickerhamomyces anomalus killer strain in the malaria vector Anopheles stephensi.
    Cappelli A; Ulissi U; Valzano M; Damiani C; Epis S; Gabrielli MG; Conti S; Polonelli L; Bandi C; Favia G; Ricci I
    PLoS One; 2014; 9(5):e95988. PubMed ID: 24788884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of Candida albicans Strains Isolated from Vaginal Secretion in Front of the Mycocins of Wickerhamomyces anomalus.
    Rosseto LRB; Martelli EC; da Silva JC; Nascimento BL; Junges DSB; Delabeneta MF; Paris AP; Auler ME; Menolli RA; Simão RCG; Paula CR; Gandra RF
    Probiotics Antimicrob Proteins; 2022 Jun; 14(3):595-601. PubMed ID: 35451745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and Antifungal Susceptibility of the Emerging Fungal Species,
    Sikora M; Kuthan R; Piskorska-Malolepsza K; Golas-Pradzynska M; Domański D; Augustynowicz-Kopeć E; Swoboda-Kopec E
    Pol J Microbiol; 2019 Sep; 68(3):303-308. PubMed ID: 31880875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
    Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
    J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom.
    Borman AM; Muller J; Walsh-Quantick J; Szekely A; Patterson Z; Palmer MD; Fraser M; Johnson EM
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans.
    Break TJ; Desai JV; Natarajan M; Ferre EMN; Henderson C; Zelazny AM; Siebenlist U; Hoekstra WJ; Schotzinger RJ; Garvey EP; Lionakis MS
    J Antimicrob Chemother; 2018 Jan; 73(1):151-155. PubMed ID: 29040636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.